Akums Drugs and Pharmaceuticals Limited has announced its un-audited financial results for the quarter ended June 30, 2026. The company reported a profit of ₹448.39 crore for the quarter, compared to ₹151.97 crore in the same period last year. Total income for the quarter stood at ₹4,183.79 crore.
Akums Drugs Announces Q1 FY27 Financial Results
Akums Drugs and Pharmaceuticals Limited has released its un-audited standalone financial results for the first quarter of the financial year 2027, which concluded on June 30, 2026. The company reported a significant increase in profitability and revenue compared to the prior year period.
Key Financial Highlights
Profitability
For the quarter ended June 30, 2026, Akums Drugs reported a profit of ₹448.39 crore. This marks a substantial rise from the profit of ₹151.97 crore recorded in the corresponding quarter of the previous financial year (ended June 30, 2025). The company also reported a total comprehensive income of ₹458.93 crore for the current quarter.
Revenue and Income
The total income for the quarter stood at ₹4,183.79 crore, an increase from ₹3,661.01 crore in the quarter ended March 31, 2026, and ₹3,609.98 crore in the quarter ended June 30, 2025. Revenue from operations contributed ₹3,922.75 crore, with other income adding ₹261.04 crore.
Expenses
Total expenses for the quarter were reported at ₹3,590.43 crore. The cost of materials consumed was a significant component, amounting to ₹2,535.62 crore. Employee benefits expense stood at ₹589.18 crore, while other expenses totaled ₹481.88 crore.
Other Comprehensive Income
Akums Drugs also reported other comprehensive income. Items that will not be reclassified to profit and loss included re-measurement gains on defined benefit plans, amounting to ₹14.09 crore, net of tax. Overall, other comprehensive income, net of tax, was ₹10.54 crore for the quarter.
Earnings Per Share
Basic and diluted Earnings Per Share (EPS) for the quarter ended June 30, 2026, were reported at ₹2.93.
Consolidated Financials
In addition to the standalone results, the company also presented its unaudited consolidated financial results. The consolidated revenue from operations for the quarter was ₹11,666.29 crore, with a consolidated profit for the quarter of ₹1,009.78 crore.
Deviation in Utilisation of Funds
The company also submitted a statement detailing the deviation or variation in the utilisation of funds raised from its public issue. The statement indicates that for the objects like ‘Repayment/prepayment of indebtedness of the Company’ and ‘Repayment/prepayment of indebtedness of its Subsidiaries’, there has been no deviation or variation in the utilisation of funds raised through IPO.
Source: BSE
